Enanta Pharmaceuticals Inc (ENTA)
Healthcare
Biotechnology
12.60 $
-3.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Enanta Pharmaceuticals Inc (ENTA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.0% of the shares are freely tradable; institutional investors hold 92.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
92.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
4.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
69.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
10.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
29Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HHG PLC | 13.01 | 3,784,055 | +1.5 | 03/31/2026 |
| BlackRock Inc | 10.67 | 3,103,768 | +0.9 | 03/31/2026 |
| Farallon Capital Management, L.L.C. | 9.88 | 2,871,862 | +3.6 | 03/31/2026 |
| Krensavage Asset Management, LLC | 9.86 | 2,866,138 | +3.6 | 03/31/2026 |
| Vanguard Group Inc | 7.92 | 2,301,794 | +18.7 | 12/31/2025 |
| Deep Track Capital, LP | 6.73 | 1,956,867 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.05 | 1,178,049 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 3.26 | 948,904 | +0.0 | 03/31/2026 |
| Spruce Street Capital LP | 3.21 | 932,598 | +139.3 | 03/31/2026 |
| Millennium Management LLC | 3.03 | 882,097 | +31.6 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.